Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
When planning prostate brachytherapy, do you use a bladder neck constraint?
If so, what dose constraint do you follow and how do you contour the bladder neck?
Answer from: Radiation Oncologist at Community Practice
With real time planning, try to limit it to 85 percent of the prescription dose. Smith et al., PMID 20888139
Sign in or Register to read more
14564
Related Questions
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive PSMA-avid vertebral body metastases, when do you prescribe lutetium 177 (Pluvicto) vs prophylactic spinal radiation?
As PARTIQoL was a negative study, what is the current role for proton therapy in the management of prostate cancer patients?
How long would you delay prostate radiation following use of a paclitaxel-eluting balloon dilator (optilume) for management of a recurrent urethral stricture after TURP?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
For recurrent prostate cancer after prostatectomy with soft tissue mass in the prostate fossa, is hypofractionation an option or is standard fractionation recommended?
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
What is your approach to SBRT to an entire kidney infiltrated with RCC?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?